Logo
Contact    |    Site Map    |    Careers

 

Trial_locations_btn

Ricolinostat in Lymphoma

Ricolinostat in combination with other drugs used to treat NHL has demonstrated potent killing of multiple types of lymphoma cells (NHL) in laboratory studies. Ricolinostat is thought to induce lymphoma cell death, called apoptosis, through the inhibition of a protein degradation pathway, and/or suppression of a critical cancer promoting gene (“myc”). Acetylon’s collaborators at Columbia University Medical Center have shown, in laboratory experiments, that ricolinostat can induce lymphoma cell death both alone and in combination with many different anti-cancer agents, such as proteasome inhibitors, PI3K inhibitors and Bruton’s tyrosine kinase inhibitors.